



BSH New Consultants' Meeting

Top tips for the transition to heart failure consultant

Thursday 25 January 2018, 09:30–17:15

1 Wimpole Street, London

Programme

**Programme directors: Paul Kalra (Portsmouth) /
Parminder Chaggar (Sheffield) / Kaushik Guha (Portsmouth)**

09:30–10:00	Registration – coffee	
10:00–10:10	Introduction	<i>Paul Kalra (Portsmouth)</i>
Session 1: Coping with general issues as a consultant		
10:10–10:50	The first complaint/Serious Untoward Incident	<i>Paul Kalra (Portsmouth)</i>
10:50–11:20	Coffee	
11:20–12:00	My first serious complication	<i>Andrew Clark (Hull)</i>
12:00–12:40	Dealing with difficult consultant colleagues and the trainee in difficulty	<i>Iain Squire (Leicester)</i>
12:40–13:40	Lunch	
Session 2: Heart failure issues in consultant life		
13:40–14:15	How do I set up a MDT and a link between primary and secondary care?	<i>Jayne Masters (Southampton)</i>
14:15–14:55	Writing a business case for heart failure specialist nurse expansion	<i>Louise Clayton (Leicester)</i>
14:55–15:25	Tea	
15:25–15:55	Clinical coding pitfalls, National Heart Failure Audit and Heart Failure Best Practice Tariff	<i>Lisa Anderson (London)</i>
15:55–16:25	How do I get involved with regional and national HF Research?	<i>Andrew Clark (Hull)</i>
16:25–17:15	Minimising error at work by looking after ourselves: a human factors overview	<i>Peter Brennan (Portsmouth)</i>

This full day meeting will provide opportunities for new and recently appointed Heart Failure Consultants (typically within their first 2-3 years) to network with others at a similar stage of their careers and gain insights and practical advice from those with experience in this role.

CPD accreditation is being sought from the Federation of the Royal Colleges of Physicians of the United Kingdom.

The registration form for the meeting is available on the BSH website: <http://www.bsh.org.uk/meetings/bsh-future-meetings/>

The cost of the day is £25 for BSH members and £75 for non-members.

**The BSH gratefully acknowledges the support provided for this meeting
by **Novartis Pharmaceuticals** and **Vifor Pharma****